Should Patients With Ischemic Stroke or Transient Ischemic Attack With Atrial Fibrillation and Microbleeds Be Anticoagulated?

@article{Shoamanesh2017ShouldPW,
  title={Should Patients With Ischemic Stroke or Transient Ischemic Attack With Atrial Fibrillation and Microbleeds Be Anticoagulated?},
  author={Ashkan Shoamanesh and Andreas Charidimou and Mukul Sharma and Robert G. Hart},
  journal={Stroke},
  year={2017},
  volume={48},
  pages={3408–3412}
}
The risk of atrial fibrillation-associated ischemic stroke can be significantly mitigated by anticoagulant therapy with a proven 67% relative risk reduction in ischemic stroke compared with no antithrombotic use.1 Despite this significant therapeutic effect, there still exists substantial underuse of anticoagulants.2 This underuse is driven by exaggerated concerns for anticoagulant-related bleeding complications and in particular, hemorrhagic stroke.3 This concern is further amplified in… Expand
Microbleeds and Outcome in Patients With Acute Ischemic Stroke and Atrial Fibrillation Taking Anticoagulants
  • Kang-Ho Choi, Ja-Hae Kim, +6 authors Ki-Hyun Cho
  • Medicine
  • Stroke
  • 2020
TLDR
The study results indicate that the risk of future MACCE increased with increasing CMB burden in patients with AIS and atrial fibrillation taking OACs, while the anatomic location of CMBs did not influence therisk of futureMACCE. Expand
Oral Anticoagulation in Asian Patients With Atrial Fibrillation and a History of Intracranial Hemorrhage
TLDR
NOAC might be a more effective and safer treatment option for Asian patients with nonvalvular AF and a prior history of ICH, and was associated with a significant lower risk of I CH and ischemic stroke compared with warfarin. Expand
Risk of intracerebral haemorrhage in Chinese patients with atrial fibrillation on warfarin with cerebral microbleeds: the IPAAC-Warfarin study
TLDR
In Chinese patients with AF on warfarin, presence of multiple CMBs may be associated with higher rate of ICH than ischaemic stroke, and larger studies through international collaboration are needed to determine the risk:benefit ratio of oral anticoagulants in patients withAF of different ethnic origins. Expand
Antiplatelet Therapy in Cerebral Small Vessel Disease
TLDR
Current data does not support withholding antiplatelet therapy where otherwise indicated in patients with cerebral microbleeds on MRI or those who have suffered intracerebral hemorrhage, andAntiplatelet monotherapy appears to provide persistent secondary stroke prevention in patientswith lacunar stroke. Expand
Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial.
TLDR
Microbleeds mark an increased risk of recurrent stroke, ischemic stroke, and all-cause mortality in patients with a history of stroke and microbleeds on magnetic resonance imaging in the NAVIGATE ESUS trial. Expand
Evolving Approaches to Antithrombotics in Stroke Prevention and Treatment
TLDR
A review of the results of recent randomized clinical trials that build upon information gleaned from prior studies on the potential benefit of combined antiplatelet and anticoagulant therapy for stroke prevention. Expand
Are lobar microbleeds of diagnostic value in the community?
TLDR
Whether strictly lobar CMBs have the same diagnostic accuracy for CAA in the general population remains uncertain, and their value in this setting has come into question following disappointing positive and negative predictive values for probable CAA reported. Expand
Clinical perspectives on ischemic stroke
TLDR
With the advent of more stroke models that include one or more relevant comorbidities, it may be possible to identify effective treatments that may translate into new treatments at the clinical level. Expand
Cerebral amyloid angiopathy: diagnosis and potential therapies
TLDR
A literature search was conducted using MEDLINE on the topics of imaging, biomarkers, ICH prevention and treatment trials in CAA, focusing on its current diagnosis and management and opportunities for future therapeutic approaches. Expand
Cerebral microbleeds: from depiction to interpretation
TLDR
The present review addresses clinical dilemmas and the value of CMBs as diagnostic and prognostic markers for future vascular events and harmonising imaging parameters across research studies remains necessary to improve cross-study comparisons. Expand
...
1
2
...

References

SHOWING 1-10 OF 35 REFERENCES
Embolic Stroke, Atrial Fibrillation, and Microbleeds: Is There a Role for Anticoagulation?
A 73-year-old man presents with an ischemic stroke. Work-up reveals paroxysmal atrial fibrillation (AF), and magnetic resonance imaging (MRI) shows a small cortical infarct and 8 incidental corticalExpand
The Clinical Relevance of Microbleeds in Stroke study (CROMIS-2): rationale, design, and methods
TLDR
It is hypothesized that cerebral microbleeds and other markers of cerebral small vessel disease on magnetic resonance imaging, and genetic polymorphisms are associated with an increased risk of oral anticoagulant-associated intracerebral hemorrhage, with potential to improve risk prediction. Expand
MRI Screening for Chronic Anticoagulation in Atrial Fibrillation
TLDR
MRI screening appears most appropriate for a subset of atrial fibrillation patients, such as those with intermediate stroke risk, and may provide reassurance for clinicians whose concerns for ICH tend to outweigh benefits of anticoagulation. Expand
Intracerebral haemorrhage risk in microbleed-positive ischaemic stroke patients with atrial fibrillation: Preliminary meta-analysis of cohorts and anticoagulation decision schema
TLDR
The presence of CMBs in cohorts of ischaemic stroke patients is associated with a 4-fold increase in subsequent ICH risk (Class III evidence) and a simple data-driven anticoagulation schema is proposed which awaits validation and refinement as new prospective data are accumulated. Expand
The clinical relevance of cerebral microbleeds in patients with cerebral ischemia and atrial fibrillation
TLDR
Further study is warranted to assess larger numbers of patients to determine appropriate antithrombotic use in this high-risk population and determine the future risk of intracerebral hemorrhage and cerebral infarction. Expand
Cerebral microbleeds and white matter hyperintensities in cardioembolic stroke patients due to atrial fibrillation: single-centre longitudinal study
TLDR
A single centre longitudinal study to investigate CMBs and white matter hyperintensities (WMH) and the risk of future stroke in ischaemic stroke patients with atrial fibrillation, which provides useful data to guide power calculations and likely effect sizes relevant for ongoing and future larger studies and clinical trials. Expand
Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)
TLDR
HDER is at least as effective and is safer than warfarin, regardless of the presence or the absence of previous IS or TIA, and annualized intracranial hemorrhage rates were lower with HDER than with warfar in this prespecified subgroup analysis. Expand
Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation
TLDR
An updated meta-analysis of all currently available randomized trials that extends observations about the efficacy and safety of antithrombotic therapies for preventing stroke in patients who have atrial fibrillation is presented. Expand
Recurrent stroke risk and cerebral microbleed burden in ischemic stroke and TIA
TLDR
CMBs are associated with increased stroke risk after IS or TIA, with increasing CMB burden (compared to no CMBs), the risk of ICH increases more steeply than that of IS. Expand
Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial
TLDR
In patients with atrial fibrillation, apixaban is similarly effective whether or not patients have had a previous stroke or TIA, and the absolute benefits might be greater in these patients. Expand
...
1
2
3
4
...